

CERTIFICATE OF MAILING

I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS BEING DEPOSITED WITH
THE UNITED STATES POSTAL SERVICE AS FIRST-CLASS MAIL IN AN ENVELOPE
ADDRESSED TO: MAIL STOP RESPONSE TO OFFICE ACTIONS, COMMISSIONER
FOR PATENTS, P.O. BOX 1450, ALEXANDRIA, VA 22313-1450 ON

21 January, 2005

Jackie Bella Vecchia
NAME OF PERSON MAILING DOCUMENT

January 21, 2005
DATE

Attorney Docket No. PG3433

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Bonnefoy, *et al.* 21 January 2005
Serial No.: 09/674,716 Group Art Unit No.: 1644
Filed: 22 January 2001 Examiner: Phuong Huynh
For: Humanised Anti-CD23 Antibody

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22323-1450

**REVOCATION OF PRIOR POWER OF ATTORNEY BY ASSIGNEE
WITH NEW POWER OF ATTORNEY
AND CHANGE OF CORRESPONDENCE ADDRESS**

Sir:

As assignee of record of the entire interest in the above-identified patent application, I hereby revoke all previous powers of attorney given and hereby appoint the practitioners associated with the Customer Number provided below to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith:

Customer Number 20462.

Please change the correspondence address for the above-identified application to the address associated with Customer Number 20462.

Assignee's attorneys may be reached by telephone at (610) 270-5009 and by facsimile at (610) 610-5090.

Date: 21 January 2005

Stephen Venetianer
Stephen Venetianer
Vice-President, Corporate Intellectual Property

GlaxoSmithKline
Corporate Intellectual Property - UW2220
P.O. Box 1539
King of Prussia, Pennsylvania 19406-0939

BEST AVAILABLE COPY



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Bonnefoy, *et al.* 21 January 2005
Serial No.: 09/674,716 Group Art Unit No.: 1644
Filed: 22 January 2001 Examiner: Phuong Huynh
For: Humanised Anti-CD23 Antibody

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22323-1450


ASSIGNEE CERTIFICATION
STATEMENT UNDER 37 C.F.R. 3.73(b)

SmithKline Beecham Corporation, a corporation organized in the Commonwealth of Pennsylvania, states that it is the assignee of the entire right, title and interest in the patent application identified above by virtue of the chain of title from the inventors of the patent application identified above, to the current assignee as shown below:

1. From the inventors, BONNEFOY, CROWE, ELLIS, RAPSON and SHERIN, to Glaxo Wellcome Inc. The document was recorded in the United States Patent and Trademark Office at Reel/Frame 013250/0788, a copy thereof is attached.

Additional document in the chain of title: Articles of Merger of SmithKline Beecham Corporation showing the merged entity of Glaxo Wellcome Inc., effective March 31, 2001, a copy is attached.

The undersigned, whose title is supplied below, is authorized to act on behalf of the assignee, SmithKline Beecham Corporation.

Signature: 
Name: Stephen Venetianer
Title: Vice-President, Corporate Intellectual Property
Date: 21 January 2005

GlaxoSmithKline
Corporate Intellectual Property - UW2220
P.O. Box 1539
King of Prussia, Pennsylvania 19406-0939

Assignment

WHEREAS, I/we, **Jean-Yves Marcel Paul BONNEFOY**, a citizen of France; **Scott James CROWE**, **Jonathan Henry ELLIS**, **Nicholas Timothy RAPSON** all citizens of the United Kingdom; and **Jean SHEARIN**, a citizen of the United States; each residing respectively at Cedex, France; Hertfordshire, United Kingdom; Hertfordshire, United Kingdom; Kent, United Kingdom and Durham, North Carolina has/have invented or discovered certain improvements in **ANTIBODIES TO CD23, DERIVATIVES THEREOF, AND THEIR THERAPEUTIC USES** hereinafter referred to as said invention and improvements for which a patent application, serial number GB9809839.5 was filed 9 May 1998 in the United Kingdom and for which a an international patent application, PCT/GB99/01434 was filed on 7 May 1999 designating the United States of America.

WHEREAS, **GLAXO WELLCOME INC.**, a corporation organized and existing under and by virtue of the laws of the State of North Carolina and having its principal place of business at Five Moore Drive, Research Triangle Park, North Carolina 27709, USA, is desirous of acquiring the whole right, title and interest in and to said invention and improvements and said application, and in and to any Letters Patent to be obtained therefor, in the United States, its territories and possessions; and

WHEREAS, **GLAXO GROUP Ltd.**, a company incorporated in England, whose registered office is at Glaxo Wellcome House, Berkeley Avenue, Greenford, Middlesex, UB6 ONN, UK, is desirous of acquiring the whole right, title and interest in and to said invention and improvements, and in and to any applications for said invention and improvements and any Letters Patent to be obtained therefor, in all countries other than the United States, its territories and possessions;

NOW, THEREFORE, to all whom it may concern, be it known that I/we, **Jean-Yves Marcel Paul BONNEFOY**, **Scott James CROWE**, **Jonathan Henry ELLIS**, **Nicholas Timothy RAPSON** and **Jean SHEARIN** for good and valuable consideration unto me/us moving, the receipt whereof is hereby

acknowledged, have sold, assigned and transferred, and by these presents do sell, assign and transfer my/our whole right, title and interest in and to said invention and improvements to said GLAXO WELLCOME INC., throughout the United States of America, its territories and possessions, and in and to said application and any extensions, reissues, continuations, continuations-in-part, and any divisions thereof, and in and to any and all Letters Patent of the United States of America;

AND, my/our whole right, title and interest in and to said invention and improvements to GLAXO GROUP Ltd., in all other countries throughout the world, and in to any applications in said other countries, and continuations-in-part, patents of addition, revalidation patents, patents of importation, registrations, and any renewals, extensions and divisions thereof, and in and to any and all Letters Patent of said all other countries which may be granted on said invention and improvements including any priority rights under the International Convention.

AND, I/we do hereby authorize and request the issue of any Letters Patent in the respective areas referred to, to said GLAXO WELLCOME INC. or GLAXO GROUP Ltd., as assignees of my/our whole right, title and interest in and to the same for the sole use and behoof of the said assignees, their successors and assigns as their interests appear herein;

AND, I/we warrant that I/we have not knowingly conveyed to others any right in said invention, improvements, applications or patents or any license to use the same or to make, use or sell anything embodying or utilizing said invention and improvements and that I/we have good right to assign the same to GLAXO WELLCOME INC. and GLAXO GROUP Ltd.;

AND, I/we the undersigned Jean-Yves Marcel Paul BONNEFOY, Scott James CROWE, Jonathan Henry ELLIS, Nicholas Timothy RAPSON and Jean SHEARIN for the consideration aforesaid, do hereby agree that I/we or my/our executors or legal representatives, will provide information and make, execute and deliver any and all other instruments in writing, and any and all further acts, application papers, affidavits.

assignments and other documents which may be necessary or desirable to more effectually secure to and vest in said GLAXO WELLCOME INC. and GLAXO GROUP Ltd., their successors and assigns, the whole right, title and interest in and to the said invention and improvements, applications, Letters Patent, rights, title and interest hereby sold, assigned and conveyed, or intended so to be. *This assignment should be deemed effective as of 09 May 1998.*

IN WITNESS WHEREOF, I/we have hereunto set my/our hand(s) and affixed my/our seal(s) on the date(s) indicated below.

Inventor: Jean-Yves Marcel Paul BONNEFOY

Date

State of: _____

County of: _____

On the date(s) indicated, before me personally came Jean-Yves Marcel Paul BONNEFOY known to me to be the individual(s) described in the foregoing Assignment and who acknowledged and executed the same in my presence.

Notary: _____

My Commission Expires: _____

Inventor: Scott James CROWE

Date

State of: _____

County of: _____

On the date(s) indicated, before me personally came Scott James CROWE known to me to be the individual(s) described in the foregoing Assignment and who acknowledged and executed the same in my presence.

Notary: _____

My Commission Expires: _____

Inventor: Jonathan Henry ELLIS

Date

Docket Number

State of: _____
County of: _____

On the date(s) indicated, before me personally came **Jonathan Henry ELLIS** known to me to be the individual(s) described in the foregoing Assignment and who acknowledged and executed the same in my presence.

Notary: _____

My Commission Expires: _____

Inventor: **Nicholas Timothy RAPSON**

Date

State of: _____
County of: _____

On the date(s) indicated, before me personally came **Nicholas Timothy RAPSON** known to me to be the individual(s) described in the foregoing Assignment and who acknowledged and executed the same in my presence.

Notary: _____

My Commission Expires: _____

Jean Shearin
Inventor: **Jean SHEARIN**

11/28/00
Date

State of: NC
County of: Wake

On the date(s) indicated, before me personally came **Jean SHEARIN** known to me to be the individual(s) described in the foregoing Assignment and who acknowledged and executed the same in my presence.

Notary: Eleen M. Norton

My Commission Expires: 2/5/2001

ASSIGNMENT

WHEREAS WE, Jean-Yves Marcel Paul BONNEFOY, residing at Institute de Recherche Pierre Fabre, 74164 Saint-Julien-en-Genevois, France, (hereinafter called "the inventor(s)") have invented or discovered "Antibody" (hereinafter called "the invention") for which an application for Letters Patent in the United States of America was originally filed as International Application No. PCTPCT/GB99/01434 on 07 May 1999 (hereinafter called "the application"), and

WHEREAS the invention belongs to our employer, namely GLAXO WELLCOME RESEARCH AND DEVELOPMENT SA, now known as Serono Pharmaceutical Research Institute, a division of Ares-Serono International SA, a company incorporated in Switzerland whose registered address is 14, chemin des Aulx, CH-1228 Plan les Ouates, and

WHEREAS GLAXO RESEARCH AND DEVELOPMENT LIMITED, a company incorporated in England whose registered address is Glaxo Wellcome House, Berkeley Avenue, Greenford, Middlesex UB6 0NN, England, is desirous of acquiring from GLAXO WELLCOME RESEARCH AND DEVELOPMENT SA the whole right, title and interest in and to the invention and the application throughout all territories of the United States of America, and

WHEREAS GLAXO WELLCOME RESEARCH AND DEVELOPMENT SA and GLAXO RESEARCH AND DEVELOPMENT LIMITED have authorised and requested my making the application, and

WHEREAS GLAXO WELLCOME INC., a corporation organised and existing under and by virtue of the laws of the State of North Carolina and having its principal place of business at Five Moore Drive, Research Triangle Park, North Carolina 27709, USA is desirous of acquiring from GLAXO RESEARCH AND DEVELOPMENT LIMITED the whole right, title and interest in and to the invention and the application in respect of the United States of America;

NOW, THEREFORE, to all whom it may concern be it known that we, the inventors, hereby confirm the ownership by GLAXO WELLCOME RESEARCH AND DEVELOPMENT SA of the invention and the application by operation of law and, if under the law of the United States of America we the inventors have any ownership right, title and interest in the invention and the application (which I do not believe to be the case and claim no ownership right, title or interest in the invention and the application based on the law of Switzerland), we the inventors nevertheless hereby assign and transfer such ownership right, title and interest in and to the invention and the application to GLAXO WELLCOME RESEARCH AND DEVELOPMENT SA which in turn hereby assigns and transfers to GLAXO RESEARCH AND DEVELOPMENT LIMITED its whole right, title and interest in and to the invention and the application. GLAXO RESEARCH AND DEVELOPMENT LIMITED in turn hereby assigns and transfers to GLAXO WELLCOME INC. its whole right, title and interest in and throughout the United States of America in and to the invention and the application and in and to any priority rights in respect of the invention and the application and in and to any divisional application, continuation or continuation in part application thereof, and in and to any extension or re-issue thereof, and we the inventors and GLAXO WELLCOME RESEARCH AND DEVELOPMENT SA and GLAXO RESEARCH AND DEVELOPMENT LIMITED hereby authorise and request any patent arising therefrom in the United States of America be issued to GLAXO WELLCOME INC.

AND GLAXO WELLCOME RESEARCH AND DEVELOPMENT SA and GLAXO RESEARCH AND DEVELOPMENT LIMITED hereby, and we the inventors for ourself and our respective executors and legal representatives hereby, agree to provide information and make execute and deliver any and all other instruments in writing, and any and all further acts, applications, papers, affidavits, assignments and other documents which may be possible and are necessary or desirable to more effectually secure to and vest in GLAXO WELLCOME INC., its successors and assigns, the whole right, title and interest in and to the invention and the application hereby assigned and transferred in respect of the United States of America.

IT is hereby declared that each of the transaction hereby effected does not form part of a larger transaction or of a series of transactions in respect of which the amount or value, or the aggregate amount or value, of the consideration exceeds £60,000.

IN WITNESS whereof and with effect from the 09th day of May 1998 the inventors and Graham Brereton as Attorney of GLAXO RESEARCH AND DEVELOPMENT LIMITED and ~~X~~ **TIMOTHY N.C. WELLS** of SERONO PHARMACEUTICAL RESEARCH INSTITUTE (formerly GLAXO WELLCOME RESEARCH AND DEVELOPMENT SA) by virtue of Powers of Attorney granted by SERONO PHARMACEUTICAL RESEARCH INSTITUTE and GLAXO RESEARCH AND DEVELOPMENT LIMITED respectively have hereunto set their respective hands.

SIGNED by Jean-Yves Marcel Paul BONNEFOY: ~~X~~ 

in the presence of:

 **Nuno SANTOS MARM**

SIGNED by Graham George Brereton as the Attorney of GLAXO RESEARCH AND DEVELOPMENT LIMITED:



SIGNED by ~~X~~ 

TIMOTHY N.C. WELLS
of SERONO PHARMACEUTICAL RESEARCH INSTITUTE, a division of Ares-Serono International SA (formerly GLAXO WELLCOME RESEARCH AND DEVELOPMENT SA):

ASSIGNMENT

WHEREAS I/WE, ~~Scott James CROWE~~ ^{JAMES SCOTT CROWE}, Jonathan Henry ELLIS and Nicholas Timothy RAPSON residing at Glaxo Wellcome plc, Gunnels Wood Road, Stevenage, Hertfordshire SG1 2NY, GB (hereinafter called "the inventor(s)") have invented or discovered "Antibody" (hereinafter called "the invention") for which an application for Letters Patent in the United States of America was originally filed as International Application No. PCT/GB99/01434 on 07 May 1999 (hereinafter called "the application"), and

WHEREAS the invention, being made in the circumstances set out in Section 39(1)(a) of the United Kingdom Patents Act 1977, belongs to my/our employer, namely GLAXO WELLCOME plc, a company incorporated in England whose registered address is Lansdowne House, Berkeley Square, London W1X 6BQ, England, and

WHEREAS GLAXO RESEARCH AND DEVELOPMENT LIMITED, a company incorporated in England whose registered address is Glaxo Wellcome House, Berkeley Avenue, Greenford, Middlesex UB6 0NN, England, is desirous of acquiring from GLAXO WELLCOME plc the whole right, title and interest in and to the invention and the application, and

WHEREAS GLAXO WELLCOME plc and GLAXO RESEARCH AND DEVELOPMENT LIMITED have authorised and requested my/our making the application, and

WHEREAS GLAXO WELLCOME INC., a corporation organised and existing under and by virtue of the laws of the State of North Carolina and having its principal place of business at Five Moore Drive, Research Triangle Park, North Carolina 27709, USA is desirous of acquiring from GLAXO RESEARCH AND DEVELOPMENT LIMITED the whole right, title and interest in and to the invention and the application in respect of the United States of America;

NOW, THEREFORE, to all whom it may concern be it known that I/we, the inventor(s), hereby confirm the ownership by GLAXO WELLCOME plc of the invention and the application by operation of law under the United Kingdom Patents Act 1977 and, if under the law of the United States of America I/we the inventor(s) have any ownership right, title and interest in the invention and the application (which I/we do not believe to be the case and claim no ownership right, title or interest in the invention and the application based on the law of the United Kingdom), I/we the inventor(s) nevertheless hereby assign and transfer such ownership right, title and interest in and to the invention and the application to GLAXO WELLCOME plc. GLAXO WELLCOME plc in turn hereby assigns and transfers to GLAXO RESEARCH AND DEVELOPMENT LIMITED its whole right, title and interest in and to the invention and the application. GLAXO RESEARCH AND DEVELOPMENT LIMITED in turn hereby assigns and transfers to GLAXO WELLCOME INC. its whole right, title and interest in and throughout the United States of America in and to the invention and the application and in and to any priority rights in respect of the invention and the application and in and to any divisional application, continuation or continuation in part application thereof, and in and to any extension or re-issue thereof, and I/we the inventor(s) and GLAXO WELLCOME plc and GLAXO RESEARCH AND DEVELOPMENT LIMITED hereby authorise and request any patent arising therefrom in the United States of America be issued to GLAXO WELLCOME INC.

AND GLAXO WELLCOME plc and GLAXO RESEARCH AND DEVELOPMENT LIMITED hereby, and I/we the inventor(s) for myself/ourselves and my/our respective executors and legal representatives hereby, agree to provide information and make execute and deliver any and all other instruments in writing, and any and all further acts, applications, papers, affidavits, assignments and other documents which may be possible and are necessary or desirable to more effectually secure to and vest in GLAXO WELLCOME INC., its successors and assigns, the whole right, title and interest in and to the invention and the application hereby assigned and transferred in respect of the United States of America.


IT is hereby declared that each of the transactions hereby effected does not form part of a larger transaction or of a series of transactions in respect of which the amount or value, or the aggregate amount or value, of the consideration exceeds £60,000.

IN WITNESS whereof and with effect from the 09th day of May 1998 the inventor(s) and Graham George Brereton as Attorney of both GLAXO WELLCOME plc and GLAXO RESEARCH AND DEVELOPMENT LIMITED by virtue of Powers of Attorney granted by GLAXO WELLCOME plc and GLAXO RESEARCH AND DEVELOPMENT LIMITED respectively have hereunto set their respective hands.


SIGNED by ~~Scott James~~ CROWE:
JAMES SCOTT



in the presence of:




SIGNED by Jonathan Henry ELLIS:



In the presence of:

 PAUL FREDERICK LIFE

SIGNED by Nicholas Timothy RAPSON:



In the presence of:



SIGNED by Graham George Brereton as the Attorney of each of Glaxo Wellcome plc and Glaxo Research and Development Limited:



GlaxoWellcome

To Whom It May Concern:

I have made this copy from the original United States of America Assignment for docket number PG3433, titled: ANTIBODIES TO CD23, DERIVATIVES THEREOF, AND THEIR THERAPEUTIC USES. United States inventor Jean SHEARIN signed 28 November 2000.

Elaine Martens

Elaine Martens
Patent Paralegal

28 November 2000

Date

State of North Carolina

WAKE County

I, Keysha E. Bishop, a Notary Public for

said County and State, do hereby certify that Elaine Martens


personally appeared before me this day and acknowledged the due execution

of the foregoing instrument.. Witness my hand and official seal, this the 28 November 2000

Keysha E. Bishop

Keysha E. Bishop (Commission expires 10/28/2004)

Notary Public



Glaxo Wellcome Inc.

Five Moore Drive
PO Box 13398
Research Triangle Park, NC
27709-3398

Telephone

Fax

C O M M O N W E A L T H O F P E N N S Y L V A N I A

D E P A R T M E N T O F S T A T E

APRIL 05, 2001

TO ALL WHOM THESE PRESENTS SHALL COME, GREETING:

SMITHKLINE BEECHAM CORPORATION

I, Kim Pizzingrilli, Secretary of the Commonwealth of Pennsylvania do hereby certify that the foregoing and annexed is a true and correct photocopy of Articles of Merger restating the Articles of Incorporation in their entirety which appear of record in this department



IN TESTIMONY WHEREOF, I have hereunto set my hand and caused the Seal of the Secretary's Office to be affixed, the day and year above written.

Kim Pizzingrilli

Secretary of the Commonwealth

DPOS

200124 - 955

MAR 30 2001

Microfilm Number _____

Entity Number

533095

Filed with the Department of State on _____

Jim. Pignatelli
 Secretary of the Commonwealth JK

ARTICLES OF MERGER-DOMESTIC BUSINESS CORPORATION

25 CAS 15-1726 (Rev. 90)

In compliance with the requirements of 15 Pa.C.S. § 1926 (relating to articles of merger or consolidation), the undersigned business corporations, desiring to effect a merger, hereby state that:

1. The name of the corporation surviving the merger is: Swickline Beacham Corporation

2. (Check and complete one of the following):

☒ The surviving corporation is a domestic business corporation and the (a) address of its current registered office in this Commonwealth or (b) name of its commercial registered office provider and the county of venue is (the Department is hereby authorized to correct the following information to conform to the records of the Department):

(a) One Franklin Plaza, 200 North 16th Street, Philadelphia, PA 19102 Phila.
 Number and Street City State Zip County

(b) c/o: _____
 Name of Commercial Registered Office Provider

For a corporation represented by a commercial registered office provider, the county in (b) shall be deemed the county in which the corporation is located for venue and official publication purposes.

The surviving corporation is a qualified foreign business corporation incorporated under the laws of _____ and the (a) address of its current registered office in this Commonwealth or (b) name of its commercial registered office provider and the county of venue is (the Department is hereby authorized to correct the following information to conform to the records of the Department):

(a) _____
 Number and Street City State Zip County

(b) c/o: _____
 Name of Commercial Registered Office Provider

For a corporation represented by a commercial registered office provider, the county in (b) shall be deemed the county in which the corporation is located for venue and official publication purposes.

The surviving corporation is a nonqualified foreign business corporation incorporated under the laws of _____ and the address of its principal office under the laws of such domiciliary jurisdiction is:

_____ City State Zip
 Number and Street

3. The name and the address of the registered office in this Commonwealth or name of its commercial registered office provider and the county of venue of each other domestic business corporation and qualified foreign business corporation which is a party to the plan of merger are as follows:

Name of Corporation	Address of Registered Office or Name of Commercial Registered Office Provider	County
<u>Glaxo Wellcome Inc.</u>	<u>CT Corporation System</u>	<u>Philadelphia</u>

200124 - 956

OSCB:15-1926 (Rev 901-2)

4. (Check, and if appropriate complete, one of the following):

☐ The plan of merger shall be effective upon filing these Articles of Merger in the Department of State.

☒ The plan of merger shall be effective on: March 31, 2001 at 11:30 p.m.
Date Hour

5. The manner in which the plan of merger was adopted by each domestic corporation is as follows:

Name of Corporation

Manner of Adoption

SmithKline Beecham CorporationAdopted by the directors and shareholders pursuant to 15 Pa.C.S. § 1924(a).

6. (Strike out this paragraph if no foreign corporation is a party to the merger). The plan was authorized, adopted or approved, as the case may be, by the foreign business corporation (or each of the foreign business corporations) party to the plan in accordance with the laws of the jurisdiction in which it is incorporated.

7. (Check, and if appropriate complete, one of the following):

☒ The plan of merger is set forth in full in Exhibit A attached hereto and made a part hereof.

☐ Pursuant to 15 Pa.C.S. § 1901 (relating to omission of certain provisions from filed plans) the provisions, if any, of the plan of merger that amend or constitute the operative Articles of Incorporation of the surviving corporation as in effect subsequent to the effective date of the plan are set forth in full in Exhibit A attached hereto and made a part hereof. The full text of the plan of merger is on file at the principal place of business of the surviving corporation, the address of which is:

Number and Street

City

State

Zip

County

IN TESTIMONY WHEREOF, the undersigned corporation or each undersigned corporation has caused these Articles of Merger to be signed by a duly authorized officer thereof this March day of 2001.

SMITHKLINE BEECHAM CORPORATION

(Name of Corporation)

BY: Donald F. Farman

(Signature)

WIT: Donald F. Farman, SecretaryGLAXO WELLCOME INC.

(Name of Corporation)

BY: Paul A. Holcombe, Jr.

(Signature)

WIT: Paul A. Holcombe, Jr., Secretary

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☐ FADED TEXT OR DRAWING
- ☐ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☒ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.